Inflammation in atherosclerosis: A cause or a result of vascular disorders?

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 9, 2012, Pages 1978-1990

  Manduteanu, Ileana ^a   Simionescu, Maya ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

Author keywords

Atherosclerosis; Cardiovascular diseases; Dyslipidaemia; Endothelial dysfunction; Inflammation; Lipoproteins

Indexed keywords

ANIMAL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; DISEASE MODEL; DYSLIPIDEMIA; HUMAN; INFLAMMATION; LYMPHOCYTE; MAST CELL; MONOCYTE; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; LYMPHOCYTES; MAST CELLS; MONOCYTES; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS; THROMBOSIS;

EID: 84865444770     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01552.x     Document Type: Review

References (106)

1. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54: 2129-38.
2. Millonig G, Malcom GT, Wick G. Early inflammatory-immunological lesions in juvenile atherosclerosis from the pathobiological determinants of atherosclerosis in youth (PDAY)-study. Atherosclerosis. 2002; 160: 441-8.
3. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006; 47: C19-31.
4. Simionescu N, Vasile E, Lupu F, et al. Prelesional events in atherogenesis: accumulation of extracellular cholesterol rich liposomes in the arterial intima and cardiac valves of hyperlipidemic rabbits. Am J Pathol. 1986; 123: 85-101.
5. VanderLaan PA, Reardon CA, Getz GS. Site-specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol. 2004; 24: 12-22.
6. Davies PF, Civelek M, Fang Y, et al. Endothelial heterogeneity associated with regioneal athero-susceptibility and adaptation to disturbed flow in vivo. Semin Thromb Haemost. 2010; 36: 265-75.
7. Davies PF. Endothelial transcriptome profiles in vivo in complex arterial flow fields. Ann Biomed Eng. 2008; 36: 563-70.
8. Chatzizisis YS, Coskun AU, Jonas M, et al. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007; 49: 2379-93.
9. Liu Y, Chen BP, Lu M, et al. Shear stress activation of SREBP1 in endothelial cells is mediated by integrins. Arterioscler Thromb Vasc Biol. 2002; 22: 76-81.
10. Passerini AG, Polacek DC, Shi C, et al. Coexisting proinflammatory and antioxidative endothelial transcription profiles in a disturbed flow region of the adult porcine aorta. Proc Natl Acad Sci USA. 2004; 101: 2482-7.
11. Hajra L, Evans AI, Chen M, et al. The NF-kB signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci USA. 2000; 97: 9052-7.
12. Gimbrone MA Jr, Topper JN, Nagel T, et al. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann NY Acad Sci. 2000; 902: 203-9.
13. Volger OL, Fledderus JO, Kisters N, et al. Distinctive expression of chemokines and transforming growth factor-beta signaling in human arterial endothelium during atherosclerosis. Am J Pathol. 2007; 171: 326-37.
14. Dai G, Vaughn S, Zhang Y, et al. Biomechanical forces in atherosclerosis-resistant vascular regions regulate endothelial redox balance via phosphoinisitol 3-kinase/Akt-dependent activation of Nrf2. Circ Res. 2007; 101: 723-33.
15. Civelek M, Manduchi E, Rilley RJ, et al. Chronic endoplasmic reticulum stress activates unfolded protein response in arterial endothelium in regions of susceptibility to atherosclerosis. Circ Res. 2009; 105: 453-61.
16. Bartel DP. MicroRNA: target recognition and regulatory functions. Cell. 2009; 136: 215-33.
17. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol. 2007; 27: 266-74.
18. Nordestgaard BG, Hjelms E, Stender S, et al. Different efflux pathways for high and low density lipoproteins from porcine aortic intima. Arteriosclerosis. 1990; 10: 477-85.
19. Kruth HS. Localization of unesterified cholesterol in human atherosclerotic lesions. Demonstration of filipin positive, oil-Red-0-negative particles. Am J Pathol. 1984; 114: 201-8.
20. Tirziu D, Dobrian A, Tasca C, et al. Intimal thickenings of human aortas contain modified reassembled lipoproteins. Atherosclerosis. 1995; 112: 101-14.
21. Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J Lipid Res. 2009; 50: S376-81.
22. Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr Opin Lipidol. 2009; 20: 363-9.
23. Ghinea N, Leabu M, Hasu M, et al. Prelesional events in atherogenesis. Changes induced by hypercholesterolemia in the cell surface chemistry of arterial endothelium and blood monocytes, in rabbit. J Submicrosc Cytol. 1987; 19: 209-27.
24. Li C, Mollahan P, Baguneid MS, et al. A comparative study of neovascularization in atherosclerotic plaque using CD31, CD105 and transforming growth factor (TGF)-ß1. Pathobiology. 2006; 73: 192-7.
25. Stevens HY, Melchior B, Bell KS, et al. PECAM-1 is a critical mediator of atherosclerosis. Dis Model Mech. 2008; 1: 175-81.
26. Ostermann G, Fraemohs L, Baltus T, et al. Involvement of JAM-A in mononuclear cell recruitment in inflamed or atherosclerotic endothelium: inhibition by soluble JAM-A. Arterioscler Thromb Vasc Biol. 2005; 25: 729-35.
27. Zernecke A, Liehn EA, Fraemohs L, et al. Importance of junctional adhesion molecule-A for neointimal lesion formation and infiltration in atherosclerosis-prone mice. Arterioscler Thromb Vasc Biol. 2006; 26: e10-3.
28. Keiper T, Al-Fakhri N, Chavakis E, et al. The role of junctional adhesion molecule-C (JAM-C) in oxidized LDL-mediated leukocyte recruitment. FASEB J. 2005; 19: 2078-80.
29. Hirata K, Ishida T, Penta K, et al. Cloning of an immunoglobulin family adhesion molecule selectively expressed by endothelial cells. J Biol Chem. 2001; 276: 16223-31.
30. Rohatgi A, Owens AW, Khera A, et al. Differential associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule. Arterioscler Thromb Vasc Biol. 2009; 29: 1684-90.
31. Barreiro O, Yáñez-Mó M, Sala-Valdés M, et al. Endothelial tetraspanin microdomains regulate leukocyte form adhesion during extravasation. Blood. 2005; 105: 2852-61.
32. Rohlena J, Volger OL, van Buul JD, et al. Endothelial CD81 is a marker of early human atherosclerotic plaques and facilitates monocyte adhesion. Cardiovasc Res. 2009; 81: 187-96.
33. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009; 78: 539-52.
34. Weber C, Schober A, Zernecke A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol. 2004; 24: 1997-2008.
35. Umehara H, Bloom ET, Okazaki T, et al. Fractalkine in Vascular Biology. Arterioscler Thromb Vasc Biol. 2004; 24: 34-40.
36. Yang XP, Mattagajasingh S, Su S, et al. Fractalkine upregulates intercellular adhesion molecule-1 in endothelial cells through CX3CR1 and the Jak Stat 5 pathway. Circ Res. 2007; 101: 101-8.
37. Manduteanu I, Dragomir E, Calin M, et al. Resistin up-regulates fractalkine expression in human endothelial cells, lack of additive effect with TNF-alpha. Biochem Biophys Res Commun. 2009; 381: 95-101.
38. Burnett MS, Lee CW, Kinnaird TD, et al. The potential role of resistin in atherogenesis. Atherosclerosis. 2005; 182: 239-48.
39. Koenen RR, Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov. 2010; 9: 141-53.
40. Koenen RR, von Hundelshausen P, Nesmelova IV, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med. 2009; 15: 97-103.
41. Weber C, Koenen RR. Fine-tunning leukocyte response: towards a chemokine interactome. Trends Immunol. 2006; 27: 268-73.
42. Gordon S, Taylor PR. Monocyte and Macrophage heterogeneity. Nat Rev Immunol. 2005; 5: 953-64.
43. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010; 116: e74-80.
44. Weber C, Belge KU, von Hundelshausen P, et al. Differential chemokine receptor expression and function in human monocytes subpopulations. J Leukoc Biol. 2000; 67: 699-704.
45. Schlitt A, Heine GH, Blankenberg S, et al. CD14+ CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost. 2004; 92: 419-24.
46. Schirmer SH, Fledderus JO, van der Laan AM, et al. Suppression of inflammatory signaling in monocytes from patients with coronary artery disease. J Mol Cell Cardiol. 2009; 46: 177-85.
47. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 2010; 7: 77-86.
48. Carman CV, Springer TA. A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J Cell Biol. 2004; 167: 377-88.
49. Kamei M, Carman CV. New observations on the trafficking and diapedesis of monocytes. Curr Opin Hematol. 2010; 17: 43-52.
50. Wilson HM. Macrophages heterogeneity in atherosclerosis - implications for therapy. J Cell Mol Med. 2010; 14: 2055-65.
51. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol. 2009; 29: 1419-23.
52. Rosenthal-Allieri MA, Ticchioni M, Breittmayer JP, et al. Influence of b1 integrin intracytoplasmic domains in the regulation of VLA-4-mediated adhesion of human T cells to VCAM-1 under flow conditions. J Immunol. 2005; 175: 1214-23.
53. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6: 508-19.
54. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009; 6: 399-409.
55. 3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One. 2007; 2: e779.
56. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011; 12: 204-12.
57. Ait-Oufella H, Taleb S, Mallat Z, et al. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011; 31: 969-79.
58. Langer HF, Daub K, Braun G, et al. Platelets recruit human DC via Mac-1/JAM-C interaction and modulate this function in vitro. Arterioscler Thromb Vasc Biol. 2007; 27: 1463-70.
59. Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol. 2010; 134: 25-32.
60. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005; 115: 3378-84.
61. Totani L, Evangelista V. Platelet leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol. 2010; 30: 2357-61.
62. Van der Zee PM, Biro E, Ko Y, et al. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem. 2006; 52: 657-64.
63. Li X, Cong H. Platelet-derived microparticles and the potential of glycoprotein IIb/IIIa antagonists in treating acute coronary syndrome. Tex Heart Inst J. 2009; 36: 134-9.
64. Mause SF, Weber C. Microparticles protagonists of a novel communication network for intercellular information exchange. Circ Res. 2010; 107: 1047-57.
65. Baetta R, Corsini A. Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. Atherosclerosis. 2010; 210: 1-13.
66. Soehnlein O, Zernecke A, Weber C. Neutrophils launch monocyte extravasation by release of granule proteins. Thromb Haemost. 2009; 102: 198-205.
67. Metzler B, Xu Q. The role of mast cells in atherosclerosis. Int Arch Allergy Immunol. 1997; 114: 10-4.
68. Kovanen PT. Mast cells in atherogenesis: actions and reactions. Curr Atheroscler Rep. 2009; 11: 214-9.
69. Caligiuri G, Nicoletti A, Poirier B, et al. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest. 2002; 109: 745-53.
70. Binder CJ. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest. 2004; 114: 427-37.
71. Doran AC, Meller N, McNamara CA. The role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008; 28: 812-9.
72. Raines EW, Ferri N. Thematic review series: the immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res. 2005; 46: 1081-92.
73. Goettsch C, Rauner M, Hamann C, et al. Nuclear factor of activated Tcells mediates oxidized LDL-induced calcification of vascular smooth muscle cells. Diabetologia. 2011; 54: 2690-701.
74. Barlic J, Zhang Y, Murphy PM. Atherogenic lipids induce adhesion of human coronary artery smooth muscle cells to macrophages by up-regulating chemokine CX3CL1 on smooth muscle cells in a TNF α-NF-kB-dependent manner. J Biol Chem. 2007; 282: 19167-76.
75. Chen L, Frister A, Wang S, et al. Interaction of vascular smooth muscle cells and monocytes by soluble factors synergistically enhances IL-6 and MCP-1 production. Am J Physiol Heart Circ Physiol. 2009; 296: H987-96.
76. Han CI, Campbell GR, Campbell JH. Circulating bone marrow cells can contribute to neointimal formation. J Vasc Res. 2001; 38: 113-9.
77. Tiwari RL, Singh V, Barthwal MK. Macrophages: an elusive yet emerging therapeutic target of atherosclerosis. Med Res Rev. 2008; 28: 483-544.
78. Tabas I, Tall A, Accili D. The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. Circ Res. 2010; 106: 58-67.
79. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000; 20: 1262-75.
80. Le Dall J, Ho-Tin-Noé B, Louedec L, et al. Immaturity of microvessels in haemorrhagic plaques is associated with proteolytic degradation of angiogenic factors. Cardiovasc Res. 2010; 85: 184-93.
81. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2008; 28: 2108-14.
82. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69: 562-73.
83. Leclercq A, Houard X, Loyau S, et al. Topology of protease activities reflects atherothrombotic plaque complexity. Atherosclerosis. 2007; 191: 1-10.
84. Lijnen HR. Metalloproteins in development and progression of vascular disease. Pathophysiol Haemost Thromb. 2003-2004; 33: 275-81.
85. Carmeliet P, Moons L, Lijnen R, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet. 1997; 17: 439-44.
86. Newby AC. Matrix metalloproteinases regulate migration, proliferation and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 2006; 69: 614-24.
87. Lupu F, Heim DA, Bachmann F, et al. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1995; 15: 1444-55.
88. Orbe J, Barrenetxe J, Rodriguez JA, et al. Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism. Circulation. 2011; 124: 2909-19.
89. Dhume A, Soundararajan K, Hunter W, et al. Comparison of vascular smooth muscle cell apoptosis and fibrous cap morphology in symptomatic and asymptomatic carotid artery disease. Ann Vasc Surg. 2003; 17: 1-8.
90. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009; 27: 165-97.
91. Rudd JFH, Narula J, Strauss HW, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography. Ready for prime time? J Am Coll Cardiol. 2010; 55: 2527-35.
92. Kolodgie FD, Nakazawa G, Sangiorgi G, et al. Pathology of atherosclerosis and stenting. Neuroimaging Clin N Am. 2007; 17: 285-310.
93. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004; 109: 1594-602.
94. Crossman DC, Morton AC, Gunn JP, et al. Investigation of the effects of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-Heart Study). Trials. 2008; 9: 8.
95. Klingenberg R, Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J. 2009; 30: 2838-44.
96. Libby P, DiCarli M, Weissleder R. The vascular biology of atherosclerosis and imaging targets. J Nucl Med. 2010; 51: 33S-7S.
97. Bentzon JF, Weile C, Sondergaard CS, et al. Smooth muscle cells in atherosclerosis originate from the local vessel wall and not circulating progenitor cells in ApoE knockout mice. Arterioscler Thromb Vasc Biol. 2006; 26: 2696-702.
98. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002; 8: 403-9.
99. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008; 451: 904-13.
100. Voinea M, Manduteanu I, Dragomir E, et al. Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells-a potential tool for specific drug delivery. Pharm Res. 2005; 22: 1906-17.
101. Francis AA, Pierce GN. An integrated approach for the mechanisms responsible for atherosclerotic plaque regression. Exp Clin Cardiol. 2011; 16: 77-86.
102. Calin MV, Manduteanu I, Dragomir E, et al. Effect of depletion of monocytes/macrophages on early aortic valve lesion in experimental hyperlipidemia. Cell Tissue Res. 2009; 336: 237-48.
103. Lyon CA, Johnson JL, Williams H, et al. Soluble N-cadherin overexpression reduces features of atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2009; 29: 195-201.
104. Jayagopal A, Linton MF, Fazio S, et al. Insights into atherosclerosis using nanotechnology. Curr Atheroscler Rep. 2010; 12: 209-15.
105. Toms TE, Panoulas VF, Kitas GD. Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiovasc Med J. 2011; 5: 64-75.
106. Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res. 2009; 50: S352-7.